EPISODE · Jul 22, 2026 · 6 MIN
今天3分钟我们来聊聊胰腺癌Ib/III期临床，首例患者已给药
from 源于细胞BioInsid的个人播客
加科思JAB-23E73泛KRAS抑制剂进入胰腺癌Ib/III期临床，首例患者已给药。其覆盖90%胰腺癌KRAS突变，I期显示38.5%客观缓解率，安全性良好，或改变癌中之王治疗格局。前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊胰腺癌Ib/III期临床，首例患者已给药
0:00
6:18
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 6 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on July 22, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!